leukemia

[Science Signaling] To design CARs with a lower activation threshold, scientists compared antigen-induced pathway signaling in human T cells expressing a current CAR construct to that in cells with endogenous TCRs.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators analyzed RNA-sequencing data of 321 primary T-cell acute lymphoblastic leukemias (T-ALLs), 20 T-ALL cell lines, and 25 normal human tissues, revealing that TET2 was transcriptionally repressed or silenced in 71% and 17% of T-ALL, respectively.

[Haematologica] Scientists showed that endoplasmic reticulum stress contributed to intestinal tissue injury during graft-versus-host disease and could be targeted pharmacologically.

[Blood] In this Phase III, open-label study, patients with chronic myeloid leukemia (CML) in chronic phase previously treated with ≥2 tyrosine kinase inhibitors (TKIs) were randomized to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily.

[Scientific Reports] Investigators showed that the long-noncoding RNA colorectal neoplasia differentially expressed (CRNDE) was overexpressed in both acute myeloid leukemia samples and cell lines. CRNDE silencing inhibited proliferation and increased apoptotic rate and cell cycle arrest of KG-1a cells.

[Galecto, Inc.] Galecto, Inc. announced the treatment of the first patient in a Phase IIa trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. The current standard of care for myelofibrosis is JAK inhibitors, but questions remain regarding side effects caused by the mechanism of action.